Evaluation of Safety of HEMOBLAST Bellows in Spine Surgery

Not Applicable

Completed

• Conditions: Surgical Bleeding
• Interventions: Device: HEMOBLAST™ Bellows; Device: absorbable gelatin sponge with thrombin

• Registration Number: NCT04734535
• Lead Sponsor: Dilon Technologies Inc.

Brief Summary

The purpose of this clinical investigation in open, elective, spine surgery is to collect data to support the removal of the neurosurgical exclusion from the currently approved indication for the use of HEMOBLAST™ Bellows. This study is primarily designed to assess safety of the device for use in spine surgery, although efficacy information will also be captured and reported.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-20
• Study First Submitted QC: 2021-01-29
• Study First Posted: 2021-02-02
• Study Start: 2021-03-08
• Primary Completion: 2024-02-05
• Study Completion: 2024-02-05
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-01
• Last Update Posted: 2024-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Subject is undergoing open, elective, spine surgery
• Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation
• Subject is 22 years of age or older
• Subject does not have an active or suspected infection at the surgical site
• Subject in whom the Investigator is able to identify a Target Bleeding Site (TBS) for which any applicable conventional means for hemostasis are ineffective or impractical
• Subject has a TBS with a Surface Bleeding Severity Scale (SBSS) score of 1, 2, or 3

Exclusion Criteria

• Subject is undergoing an emergency surgical procedure
• Subject is undergoing a laparoscopic surgery
• Subject is undergoing a cervical spine surgery
• Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding
• Subject has a platelet count < 100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery
• Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery
• Subject receiving antiplatelet medications within 5 days prior to surgery
• Subject receiving aspirin within 7 days prior to surgery
• Subject has an active or suspected infection at the surgical site
• Subject has had or has planned to receive any organ transplantation
• Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent
• Subject has a known sensitivity or allergy to Gadolinium
• The subject has a contra-indication for MRI or gadolinium contrast agent according to clinical guidelines, local regulations or manufacturer's recommendations
• Subject suffers from claustrophobia or fear of MRI, or has any contraindication to MRI (e.g., metal implants, spinal cord stimulator, etc. not suited to MRI)
• Subject has American Society of Anesthesiologists classification of > 4
• Subject has a life expectancy of less than 3 months
• Subject has a documented severe congenital or acquired immunodeficiency
• Subject has religious or other objections to porcine, bovine, or human components
• Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent
• Per investigator opinion subject is unable to fully cooperate with the study protocol.
• The product will be placed in at the site where the dura is open
• The product will be placed in the intradural or cranial space

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
investigational	HEMOBLAST™ Bellows	HEMOBLAST™ Bellows
control	absorbable gelatin sponge with thrombin	absorbable gelatin sponge with thrombin

Primary Outcome Measures

Name	Time	Method
Incidence of Unanticipated Adverse Device Effect (UADE)	3 months follow-up	incidence of UADE, for subjects treated with HEMOBLAST™, as determined by the Independent Data Monitoring Committee (IDMC).

Secondary Outcome Measures

Name	Time	Method
Adverse events (AE)	3 months follow-up	the proportion of AEs for subjects treated with HEMOBLAST™ compared to subjects treated with G+T.

Trial Locations

Locations (5)

University of Southern California; 🇺🇸 Los Angeles, California, United States

Indiana Spine Group; 🇺🇸 Carmel, Indiana, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Spectrum Medical Inc; 🇺🇸 Danville, Virginia, United States

Johns Hopkins Bayview Medical Center; 🇺🇸 Baltimore, Maryland, United States